Literature DB >> 10863695

[Vogt-Koyanagi-Harada syndrome: importance of rapid diagnosis and therapeutic intervention].

N Bouchenaki1, L Morisod, C P Herbort.   

Abstract

AIM: The Vogt-Koyanagi-Harada (VKH) syndrome is characterized by a bilateral granulomatous uveitis with exudative retinal detachments associated with systemic manifestations such as meningeal signs, cutaneous signs (poliosis, alopecia and vitiligo) and dysacousis. VKH is relatively unfrequent in Europe and Switzerland. Therefore diagnosis is often reached with some delay. Our aim here was to analyze the 3 patients for whom the diagnosis was reached less than 15 days after the first signs and compare their evolution to seven patients for whom diagnosis was known one month or more after the first signs. PATIENTS AND METHODS: Retrospective and partially prospective study of patients seen at uveitis clinic in Lausanne from 1990 to 1999 for whom an ICG angiographic work-up had been performed in addition to the usual clinical and fluoresceinic work-up. The frequency of VKH in our collective was calculated; symptoms and signs, paraclinical investigations, laboratory work-up, delay from first signs to diagnosis, the management and the evolution were the criteria analyzed. In particular the patients with early diagnosis and early treatment were analyzed and compared to the rest of the collective. Diagnosis was based on the criteria of the American Uveitis Society. Between 1990 and 1999, 14 patients with the diagnosis of VKH were seen (1.2% of our collective of uveitis patients). The 10 patients having had a work-up including ICG angiography in addition to the classical work-up were included in this study.
RESULTS: The diagnosis was reached in less than 2 weeks in 3 patients. In all 3 patients inflammation was controlled after treatment. Two patients with a follow-up without recurrence of respectively 36 and 54 months were considered as healed. The last case had no recurrence after nine months but still was under therapy. Whereas clinical examination and fluorescein angiography failed to show any sequels in the 2 "healed" patients, ICG angiography showed numerous zones of hypofluorescence indicating choroidal scarring. For the 7 other cases, the diagnosis was reached one month or more after the first symptoms or signs and they all evolved in the chronic recurrent fashion. ICG angiography contributed to the rapid diagnosis in 2/3 patients with early diagnosis and was an essential parameter for the choroidal follow-up in 9/10 patients.
CONCLUSION: This study shows that it is essential to rapidly reach the diagnosis of VKH and treat the patients vigorously without delay. By showing choroidal lesions not seen by the clinical examination or fluorescein angiography. ICG angiography is essential for a correct work-up and follow-up of choroidal lesions in VKH. In our two "healed" patients it was the only mean to show choroidal sequellae.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10863695     DOI: 10.1055/s-2000-10987

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  8 in total

1.  Comparison of the Clinical Manifestations between Acute Vogt-Koyanagi-Harada Disease and Acute Bilateral Central Serous Chorioretinopathy.

Authors:  Woo Beom Shin; Min Kyo Kim; Christopher Seungkyu Lee; Sung Chul Lee; Hyesun Kim
Journal:  Korean J Ophthalmol       Date:  2015-11-25

2.  Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease.

Authors:  Tatsushi Kawaguchi; Shintaro Horie; Nadia Bouchenaki; Kyoko Ohno-Matsui; Manabu Mochizuki; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2009-01-17       Impact factor: 2.031

3.  Indocyanine green angiography guided management of vogt-koyanagi-harada disease.

Authors:  Nadia Bouchenaki; Carl P Herbort
Journal:  J Ophthalmic Vis Res       Date:  2011-10

Review 4.  Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

Authors:  Carl P Herbort; Ahmed M Abu El Asrar; Joyce H Yamamoto; Carlos E Pavésio; Vishali Gupta; Moncef Khairallah; Ilknur Tugal-Tutkun; Masoud Soheilian; Masuru Takeuchi; Marina Papadia
Journal:  Int Ophthalmol       Date:  2016-11-14       Impact factor: 2.031

Review 5.  Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.

Authors:  Carl P Herbort; Ilknur Tugal-Tutkun; Ahmed Abu-El-Asrar; Amod Gupta; Masaru Takeuchi; Christine Fardeau; Alireza Hedayatfar; Cristhian Urzua; Ioannis Papasavvas
Journal:  Eye (Lond)       Date:  2021-06-18       Impact factor: 3.775

6.  Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease.

Authors:  Masaru Miyanaga; Tatushi Kawaguchi; Kentaro Shimizu; Kazunori Miyata; Manabu Mochizuki
Journal:  Int Ophthalmol       Date:  2007-05-03       Impact factor: 2.029

7.  Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up.

Authors:  Carl P Herbort; Alessandro Mantovani; Nadia Bouchenaki
Journal:  Int Ophthalmol       Date:  2007-04-25       Impact factor: 2.029

8.  Work-up, diagnosis and management of acute Vogt-Koyanagi-Harada disease: a case of acute myopization with granulomatous uveitis.

Authors:  Alessandro Mantovani; Anna Resta; Carl P Herbort; Ahmed Abu El Asrar; Tatsushi Kawaguchi; Manabu Mochizuki; Annabelle A Okada; Narsing A Rao
Journal:  Int Ophthalmol       Date:  2007-05-05       Impact factor: 2.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.